Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC10A2 | Q12908 | 1/20 | 0.38 |
| ▸ | NSD2 | O96028 | 1/20 | 0.38 |
| ▸ | CASP6 | P55212 | 1/20 | 0.38 |
| ▸ | G6PD | P11413 | 1/20 | 0.38 |
| ▸ | PDE5A | O76074 | 1/20 | 0.37 |
| ▸ | DHFR | P00374 | 1/20 | 0.37 |
| ▸ | TYMS | P04818 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 3/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | MAOA | P21397 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4727095 | 0.87 | NSD2 (0.38) | NSD2CASP6G6PDDHFRTSHR | |
| SCHEMBL4726183 | 0.77 | TUBB4A (0.40) | TYMSALDH1A1CYP3A4HSD17B10TDP1 | |
| SCHEMBL4727819 | 0.77 | NSD2 (0.38) | NSD2CASP6G6PDPDE5ADHFR | |
| SCHEMBL4726086 | 0.73 | MEN1 (0.48) | SLC10A2NSD2CASP6PDE5ATSHR | |
| SCHEMBL5080779 | 0.73 | HSP90AA1 (0.53) | NSD2CASP6ALDH1A1CYP3A4MAOA | |
| SCHEMBL28248381 | 0.72 | NOS3 (0.37) | TSHRALDH1A1HSD17B10TDP1KDM4E | |
| SCHEMBL4780864 | 0.71 | CYP1A2 (0.33) | NSD2CASP6G6PDALDH1A1CYP3A4 | |
| SCHEMBL5083088 | 0.71 | TUBB4A (0.39) | NSD2CASP6G6PDTSHRALDH1A1 | |
| SCHEMBL423613 | 0.71 | CASP6 (0.70) | NSD2CASP6G6PDPDE5AALDH1A1 | |
| SCHEMBL25911059 | 0.69 | TLR8 (0.42) | SLC10A2KDM4EIDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008021210-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | COMBINATORX, INCORPORATED (US) | 2008-02-21 | — | — | WO | disclosed |
| US-20080044390-A1 | Methods and compositions for the treatment of neurodegenerative disorders | CHDI, INCORPORATED | 2008-02-21 | — | — | US | disclosed |
| US-6979740-B2 | Process for preparation of ring-substituted 8-aminoquinoline analogs as antimalarial agents | NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH (IN) | 2005-12-27 | — | — | US | disclosed |
| US-20040192724-A1 | Process for preparation of ring-substituted 8-aminoquinoline analogs as antimalarial agents | NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH DEPARTMENT OF PHARMACEUTICAL TECHNOLOGY (IN) | 2004-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040192724-A1 | Process for preparation of ring-substituted 8-aminoquinoline analogs as antimalarial agents | QDPR, SLC11A2, CYP2C8 | SLC10A2 4736/4885NSD2 2330/4885CASP6 612/4885 |
| US-20080044390-A1 | Methods and compositions for the treatment of neurodegenerative disorders | HTT, SNCA, NLN | SLC10A2 3148/4885NSD2 1540/4885CASP6 897/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.